Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 1/20 | 0.44 |
| ▸ | F11 | P03951 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.41 |
| ▸ | TTBK1 | Q5TCY1 | 4/20 | 0.41 |
| ▸ | TTBK2 | Q6IQ55 | 4/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | SUV39H1 | O43463 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9609072 | 0.86 | TTBK1 (0.45) | MAPTNPC1HPGDRAB9ATP53 | |
| SCHEMBL6917911 | 0.81 | ABCG2 (0.48) | MAPTNPC1HPGDRAB9ATP53 | |
| SCHEMBL9607698 | 0.80 | EGFR (0.48) | F9F11F7CYP2C9MAPT | |
| SCHEMBL6917896 | 0.72 | SMN1; SMN2 (0.41) | CYP2C9NPC1RAB9ASRCALDH1A1 | |
| SCHEMBL6918276 | 0.70 | NR4A1 (0.46) | MAPTNPC1RAB9ATTBK1TTBK2 | |
| SCHEMBL27886804 | 0.69 | SYK (0.49) | STK17A | |
| SCHEMBL9607702 | 0.68 | EGFR (0.49) | MAPTNPC1HPGDRAB9AMEN1 | |
| SCHEMBL1157194 | 0.66 | KEAP1 (0.63) | RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL27694739 | 0.65 | HPGD (0.51) | MAPTNPC1HPGDRAB9AMEN1 | |
| SCHEMBL18231587 | 0.64 | F9 (0.60) | F9F11F7CYP2C9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
| WO-2011017296-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | SCHERING CORPORATION (US) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | F9, F8, F12 | F9 1/4885F11 5/4885F7 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.